Phase 3 N=221 Gentian Violet Vs. Nystatin Oral Suspension for Treatment of Oropharyngeal Candidiasis
HIV-1 Infection
Primary: Number of Participants With Clinical Efficacy — 76; 73 participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 1 N=32 Pharmacokinetics and Pharmacodynamics Study of BCD-033 Compared to Rebif® in Healthy Volunteers
Healthy
Primary: Area Under Concentration-time Curve (AUC) of Interferon (IFN) Beta-1a From the Moment of Drug Administration Until 48 Hours and to Infinity(AUC(0-48) and AUC(0-∞)…
Phase 1 N=43 ATX-MS-1467 in Patients With Relapsing Forms of Multiple Sclerosis
Relapsing Remitting Multiple Sclerosis
Primary: Safety and Tolerability — 21; 22 participants
N/A N=82 Treatment of Posttraumatic Stress Disorder in Kosovar High School Students Using Mind-Body Skills Groups
Stress Disorders, Post-traumatic
Primary: Harvard Trauma Questionnaire — 2.5; 2.5; 2.0; 2.4 units on a scale
Phase 2 N=19 Sunitinib Malate in Treating Patients With Uterine Cervical Cancer That is Stage IVB, Recurrent, or Cannot Be Removed By Surgery
Cervical Adenocarcinoma · Cervical Adenosquamous Cell Carcinoma · Cervical Squamous Cell Carcinoma
Primary: Objective Response Rate (PR or CR) — 0 percentage of evalubale patients
N/A N=11 HDE Use Protocol of TheraSphere for Treatment of Unresectable HCC
Hepatocellular Carcinoma
Primary: Progression — 11 participants
Phase 3 N=2,628 CHIZAP: Community- and Health Facility-Based Intervention With Zinc as Adjuvant Therapy for Childhood Pneumonia
Pneumonia
Primary: Risk of Treatment Failure. — 267; 253 participants
Phase 4 N=544 Evaluation of Treatments to Improve Smoking Cessation Medication Adherence
Smoking · Smoking Cessation · Adherence
Primary: Self-Reported 7-Day Point-Prevalence Abstinence — 197; 181; 202; 176 participants — p=.011
Phase 3 N=340 Trial of Aripiprazole Intramuscular Depot (OPC-14597, Lu AF41155) in the Acute Treatment of Adults With Schizophrenia
Schizophrenia
Primary: Mean Change From Baseline to Endpoint in Positive and Negative Syndrome Scale (PANSS) Total Score. — -8.9; -5.0; -15.2; -8.3 Units on a scale — p=0.0005
Phase 3 N=515 Safety and Efficacy of BIBF 1120 at High Dose in Idiopathic Pulmonary Fibrosis Patients
Pulmonary Fibrosis
Primary: Annual Rate of Decline in Forced Vital Capacity (FVC) Over 52 Weeks — -239.91; -114.65 mL/year — p=<0.0001
Phase 1 N=11 A Comparison of the Bioavailability of OZ439 When Delivered Directly to the Small Intestine, or Via the Oral Route
Healthy Volunteers
Primary: OZ439 AUC0-∞ — 1230; 907; 398 ng*h/mL
Phase 3 N=527 Amoxicillin Versus Benzyl Penicillin for Treatment of Children Hospitalised With Severe Pneumonia
Pneumonia
Primary: Treatment Failure at 48 Hours (Two Full Days After Enrollment) — 20; 21 participants
Phase 3 N=212 Antibiotic Therapy in Preventing Early Infection in Patients With Multiple Myeloma Who Are Receiving Chemotherapy
Infection · Multiple Myeloma
Primary: Proportion of Patients Experiencing a Serious Bacterial Infection — 12.5; 6.8; 15.9 percentage of participants — p=0.218
Phase 3 N=133 Study Evaluating the Safety and Efficacy of Fixed-dose Once-daily Oral Aripiprazole in Children and Adolescents With Tourette's Disorder
Tourette's Disorder · Tic Disorder
Primary: Change From Baseline to Week 8 in Yale Global Tic Severity Scale (YGTSS) Total Tic Score (TTS). — -13.35; -16.94; -7.09 Units on a scale — p=0.0020
Phase 2 N=21 A Phase I/II Study of TRC105 in Metastatic Castrate Resistant Prostate Cancer (CRPC)
Prostate Cancer · Metastatic Castrate Resistant Prostate Cancer
Primary: Phase I: Maximum Tolerated Dose (MTD) of TRC105 Given Every Two Weeks. — 20 mg/kg every 2 weeks